Chiara Maria Grana - JoVE Visualize

Showing results (31-40 of 50) with videos related to

Pageof 5

Sort By:

Journal of Nuclear Medicine Technology|October 4, 2022

Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive ReviewEmran Askari, Soroush Zarehparvar Moghadam, Damian Wild, et al.

European Journal of Nuclear Medicine and Molecular Imaging|February 17, 2020

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practiceVikas Prasad, Raj Srirajaskanthan, Christos Toumpanakis, et al.

Tumori|August 1, 2020

Multidisciplinary team approach for Merkel cell carcinoma: the European Institute of Oncology experience with focus on radiotherapyDario Zerini, Filippo Patti, Francesca Spada, et al.

Critical Reviews in Oncology/Hematology|April 22, 2017

Interim 18FDG PET/CT during radiochemotherapy in the management of pelvic malignancies: A systematic reviewMahila Ferrari, Laura Lavinia Travaini, Delia Ciardo, et al.

Endocrine|February 7, 2024

Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysisManila Rubino, Giuseppe Danilo Di Stasio, Lisa Bodei, et al.

European Journal of Nuclear Medicine and Molecular Imaging|July 7, 2017

Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic reviewMarta Cremonesi, Laura Gilardi, Mahila Esmeralda Ferrari, et al.

Journal of Neuroendocrinology|April 14, 2026

The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [177Lu]Lu-DOTA-TATE: A post-authorisation safety studyJohannes Hofland, Chiara Maria Grana, Martin O Weickert, et al.

European Journal of Nuclear Medicine and Molecular Imaging|February 19, 2021

Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumorsSilvia Nicolini, Lisa Bodei, Alberto Bongiovanni, et al.

Journal of Endocrinological Investigation|October 12, 2024

Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM)Francesco Panzuto, Manuela Albertelli, Maria Luisa De Rimini, et al.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 17, 2024

A PET-Surrogate Signature for the Interrogation of the Metabolic Status of Breast CancersStefano Confalonieri, Bronislava Matoskova, Rosa Pennisi, et al.

Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:

Pageof 5

Journal of Nuclear Medicine Technology|October 4, 2022

Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive ReviewEmran Askari, Soroush Zarehparvar Moghadam, Damian Wild, et al.

European Journal of Nuclear Medicine and Molecular Imaging|February 17, 2020

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practiceVikas Prasad, Raj Srirajaskanthan, Christos Toumpanakis, et al.

Tumori|August 1, 2020

Multidisciplinary team approach for Merkel cell carcinoma: the European Institute of Oncology experience with focus on radiotherapyDario Zerini, Filippo Patti, Francesca Spada, et al.

Critical Reviews in Oncology/Hematology|April 22, 2017

Interim 18FDG PET/CT during radiochemotherapy in the management of pelvic malignancies: A systematic reviewMahila Ferrari, Laura Lavinia Travaini, Delia Ciardo, et al.

Endocrine|February 7, 2024

Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysisManila Rubino, Giuseppe Danilo Di Stasio, Lisa Bodei, et al.

European Journal of Nuclear Medicine and Molecular Imaging|July 7, 2017

Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic reviewMarta Cremonesi, Laura Gilardi, Mahila Esmeralda Ferrari, et al.

Journal of Neuroendocrinology|April 14, 2026

The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [177Lu]Lu-DOTA-TATE: A post-authorisation safety studyJohannes Hofland, Chiara Maria Grana, Martin O Weickert, et al.

European Journal of Nuclear Medicine and Molecular Imaging|February 19, 2021

Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumorsSilvia Nicolini, Lisa Bodei, Alberto Bongiovanni, et al.

Journal of Endocrinological Investigation|October 12, 2024

Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM)Francesco Panzuto, Manuela Albertelli, Maria Luisa De Rimini, et al.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 17, 2024

A PET-Surrogate Signature for the Interrogation of the Metabolic Status of Breast CancersStefano Confalonieri, Bronislava Matoskova, Rosa Pennisi, et al.

Pageof 5